|
Is the IPO window opening for biotechs? By mid year there were as many IPOs completed compared to all of 2006. The industry is also on track to have a record-breaking year for fund-raising and M&A and partnering in biotech land continues to remain red hot. Deal making in the first half of the year has been on a record pace according to the Biotech 2007 Half Year Report, which provides an in depth analysis of the deals and financings through 1H 2007. While biotech s performance on the capital markets haven t been strong, 19 biotech IPO s got out of the gate (collectively raising $1.47 billion). The Report describes these companies and looks at their post IPO share prices activity.
The Half-year Biotech Report brings you all the latest statistics and deals (January to June 2007), examines the trends and projects out what lies in store for the rest of the year. The Report also provides a detailed analysis of the performance of all of the publicly-listed biotech companies on the AMEX and NASDAQ and profiles on the 19 biotech IPO graduates in 2007.
Order your copy today.
Biotech 2007 Half Year report (PDF file)
North America & Overseas:
$175
SPECIAL: Order Biotech 2007 plus the Half Year Report and pay only
$440.
Download Sample Report
>
*Discount does not
apply to reports already purchased. The prices quoted above
reflect the 10% discount.
|
